BIOCHEMICAL AND RADIOGRAPHIC RESPONSE TO ABIRATERONE ACETATE IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER WITHOUT PREVIOUS CHEMOTHERAPY

被引：0
|
作者：
Poti, Giulia [1 ]
Giacinti, Silvana [1 ]
Macrini, Serena [1 ]
Bassanelli, Maria [1 ]
Roberto, Michela [1 ]
Aschelter, Anna Maria [1 ]
Marchetti, Paolo [1 ]
机构：
[1] Sapienza Univ, Div Oncol, St Andrea Hosp, Rome, Italy
来源：
ANTICANCER RESEARCH | 2017年 / 37卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
57
引用
收藏
页码：2084 / 2085
页数：2
相关论文
共 50 条
  • [31] Enzalutamide in Combination with Abiraterone Acetate in Bone Metastatic Castration-resistant Prostate Cancer Patients
    Efstathiou, Eleni
    Titus, Mark
    Wen, Sijin
    Troncoso, Patricia
    Hoang, Anh
    Corn, Paul
    Prokhorova, Ina
    Araujo, John
    Dmuchowski, Carl
    Melhem-Bertrandt, Amal
    Patil, Shiva
    Logothetis, Christopher J.
    EUROPEAN UROLOGY ONCOLOGY, 2020, 3 (01): : 119 - 127
  • [32] A multicentre analysis of abiraterone acetate in Canadian patients with metastatic castration-resistant prostate cancer
    Clayton, Ravinder
    Wu, Jackson
    Heng, Daniel Y.
    North, Scott A.
    Emmenegger, Urban
    Hotte, Sebastien
    Chi, Kim
    Zielinski, Rob
    Al-Shamsi, Humaid
    Chen, Leo
    Eigl, Bernhard
    CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL, 2014, 8 (9-10): : E583 - E590
  • [33] Efficacy of Enzalutamide Following Abiraterone Acetate in Chemotherapy- naive Metastatic Castration-resistant Prostate Cancer Patients
    Azad, Arun A.
    Eigl, Bernhard J.
    Murray, R. Nevin
    Kollmannsberger, Christian
    Chi, Kim N.
    EUROPEAN UROLOGY, 2015, 67 (01) : 23 - 29
  • [34] Abiraterone Acetate: A Review in Metastatic Castration-Resistant Prostrate Cancer
    Lesley J. Scott
    Drugs, 2017, 77 : 1565 - 1576
  • [35] Enzalutamide versus abiraterone acetate for the treatment of men with metastatic castration-resistant prostate cancer
    Zhang, Tian
    Zhu, Jason
    George, Daniel J.
    Armstrong, Andrew J.
    EXPERT OPINION ON PHARMACOTHERAPY, 2015, 16 (04) : 473 - 485
  • [36] LONG SURVIVAL WITH ABIRATERONE ACETATE IN AN ELDERLY PATIENT WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
    Macrini, Serena
    Poti, Giulia
    Giacinti, Silvana
    Bassanelli, Maria
    Roberto, Michela
    Aschelter, Anna Maria
    Marchetti, Paolo
    ANTICANCER RESEARCH, 2017, 37 (04) : 2085 - 2085
  • [37] Metastatic castration-resistant prostate cancer: targeting the mechanisms of resistance to abiraterone acetate and enzalutamide
    Modena, Alessandra
    Ciccarese, Chiara
    Fantinel, Emanuela
    Bimbatti, Davide
    Tortora, Giampaolo
    Massari, Francesco
    EXPERT REVIEW OF ANTICANCER THERAPY, 2015, 15 (09) : 1037 - 1048
  • [38] The hematologic parameters in metastatic castration-resistant prostate cancer patients treated with abiraterone acetate
    Onal, Cem
    Sedef, Ali Murat
    Kose, Fatih
    Oymak, Ezgi
    Guler, Ozan Cem
    Sumbul, Ahmet Taner
    Aksoy, Sercan
    Yildirim, Berna Akkus
    Besen, Ali Ayberk
    Muallaoglu, Sadik
    Mertsoylu, Huseyin
    Ozyigit, Gokhan
    FUTURE ONCOLOGY, 2019, 15 (13) : 1469 - 1479
  • [39] Erratum to: Abiraterone acetate: a guide to its use in metastatic castration-resistant prostate cancer
    Lesley J. Scott
    Lily P. H. Yang
    Katherine A. Lyseng-Williamson
    Drugs & Aging, 2012, 29 (3) : 1 - 1
  • [40] Abiraterone Acetate in metastatic castration-resistant Prostate Carcinoma: When to begin?
    Miller, Kurt
    ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 : 6 - 7
12345